Table 1.
Patient characteristics according to BRAF and NRAS mutation status
| Total patient population | BRAF | NRAS | |||
|---|---|---|---|---|---|
| WT | Mutant | WT | Mutant | ||
| Patient characteristics | |||||
| Median age (range) | 62 (25–86) | 62 (38–84) | 63 (25–86) | 63 (25–86) | 61 (43–80) |
| Male (%) | 56.5 | 60 | 50 | 57.4 | 52.9 |
| Previous primary melanoma | |||||
| Cutaneous | 57a | 34 | 22 | 44 | 12 |
| Breslow thickness | |||||
| <1 | 6 | 3 | 3 | 6 | 0 |
| 1–2 | 15 | 6 | 9 | 12 | 3 |
| 2–4 | 11 | 10 | 1 | 8 | 3 |
| >4 | 16 | 12 | 4 | 11 | 5 |
| Not available | 8 | 3 | 5 | 7 | 1 |
| Acral | 4 | 4 | 0 | 4 | 0 |
| Mucosal | 5 | 4 | 1 | 5 | 0 |
| Uveal | 5a | 5 | 0 | 4 | 1 |
| No primary | 15 | 8 | 7 | 11 | 4 |
| Serum LDH (% elevated) | 39.7 | 47.2 | 24.0 | 36.1 | 52.9 |
| Metastases at inclusionb | |||||
| Soft tissuec | 20 | 12 | 8 | 17 | 3 |
| Visceral/skeletal | 54 | 33 | 21 | 44 | 10 |
| Brain | 11 | 10 | 1 | 7 | 4 |
| Stage at inclusion | |||||
| III | 3 | 1 | 2 | 3 | 0 |
| IV | 82 | 54 | 28 | 65 | 17 |
| Clinical benefit (%) | 20 | 20.8 | 18.5 | 20.3 | 18.8 |
aOne patient presented with both uveal and cutaneous primary
bRefers to the metastatic site associated with the worst prognosis
cDefined here as subcutaneous, cutaneous or lymph node metastases